OUP user menu

Journal of Crohn's and Colitis: 9 (4)

Editor-in-Chief

Laurence J. Egan, Ireland

Associate Editors

Maria T. Abreu, USAShomron Ben-Horin, IsraelSilvio Danese, ItalyPeter Lakatos, HungaryMiles Parkes, UKGijs van den Brink, NLSéverine Vermeire, Belgium

3.562
4.023

Published on behalf of

Chicken pox infection in a three months old infant exposed in utero to Adalimumab

Anna Johnsson , Sara Avlund , Anne Grosen , Mette Julsgaard
DOI: http://dx.doi.org/10.1016/j.crohns.2012.07.020 e116-e117 First published online: 1 April 2013

Dear Sir,

Observational data suggest that anti-tumor necrosis factor (TNF)-α antibodies such as Adalimumab (ADA) is safe in pregnancy and that there is no increase in adverse birth outcomes.1 It is believed that ADA efficiently crosses the placenta in the third trimester.1 Live virus vaccines are contraindicated in infants exposed to anti-TNF-α antibodies up to the age of one year, due to the risk of severe complications.1,2 However, environmental exposure of the infant to viruses cannot be eliminated. We present a case of an infant born preterm, exposed in uteri to ADA, who …

Log in through your institution